Elidel Related Published Studies
Well-designed clinical trials related to Elidel (Pimecrolimus)
Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. [2011.06]
A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. [2011.06]
Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. [2011.02]
A bilateral comparison study of pimecrolimus cream 1% and a topical medical
device cream in the treatment of patients with atopic dermatitis. [2011]
A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in
patients with vulvar lichen sclerosus. [2011]
Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. [2010.08]
Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial. [2010.08]
Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. [2010.06]
Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial. [2010.05]
Comparative effects of pimecrolimus cream vehicle and three commercially available moisturizers on skin hydration and transepidermal water loss. [2010.05]
A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. [2010.04]
Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. [2010.03]
New treatment strategy and assessment questionnaire for external auditory canal pruritus: topical pimecrolimus therapy and Modified Itch Severity Scale. [2010.02]
The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. [2010.01]
Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. [2010]
Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus
vulgaris: a double-blind, placebo-controlled clinical trial. [2010]
An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. [2009.11]
A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. [2009.10]
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. [2009.09]
Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. [2009.09]
Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. [2009.08]
Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. [2009.05]
The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. [2009.03]
Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. [2009.01]
Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. [2009.01]
The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. [2009]
Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. [2009]
Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. [2008.11]
Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. [2008.09]
Pimecrolimus cream 1% in erosive oral lichen planus- a prospective randomized double-blind vehicle-controlled study. [2008.07.19]
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. [2008.07]
The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: A double-blind, placebo-controlled clinical trial. [2008.06.16]
A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. [2008.06]
Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. [2008.05]
Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. [2008.05]
Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. [2008.04]
Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. [2008.03.13]
A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. [2008.03.03]
Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. [2008]
A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. [2007.11]
Skin reactions to pimecrolimus cream 1% in patients allergic to propylene glycol: a double-blind randomized study. [2007.09]
Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. [2007.08]
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. [2007.08]
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. [2007.07.19]
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. [2007.04]
Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. [2007.01]
Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. [2007]
Pimecrolimus 1% cream in non-specific inflammatory recurrent balanitis. [2007]
Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. [2006.12.21]
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. [2006.09]
Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. [2006]
Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. [2006]
Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. [2006]
Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. [2006]
A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. [2005.08]
Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. [2005.06]
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. [2005.06]
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. [2005.06]
The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. [2005.04]
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. [2005.02]
Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. [2005.01]
Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. [2004.12]
Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. [2004.11]
Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. [2004.11]
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. [2004.11]
Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. [2004.10]
A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. [2004.10]
Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. [2004.06]
Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. [2004.01]
Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. [2004.01]
Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. [2004]
Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. [2004]
Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. [2003.02]
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. [2003]
Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. [2003]
The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. [2002.12]
Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. [2002.10]
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. [2002.08]
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. [2002.07]
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. [2002.04]
Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. [2002]
Well-designed clinical trials possibly related to Elidel (Pimecrolimus)
In vivo vitiligo induction and therapy model: double-blind, randomized clinical
trial. [2012]
The treatment of vulvar lichen sclerosus and female sexual dysfunction. [2011]
Topical treatment and combination approaches for vitiligo: new insights, new developments. [2010.02]
The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. [2009.02]
Emerging therapeutic targets in psoriasis. [2004.06]
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. [2001.04]
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. [2001.03]
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. [1998.12]
Other research related to Elidel (Pimecrolimus)
Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. [2012.01]
Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic
review of randomized controlled trials. [2012]
Efficacy of pimecrolimus 1 % cream in the long term management of atopic hand dermatitis. A double-blind RCT. [2011.11.23]
Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. [2011.09]
The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. [2011.07.25]
A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis. [2011.07]
The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. [2011.05]
Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic
acid emollient foam in the treatment of patients with atopic dermatitis. [2011]
Percutaneous absorption of pimecrolimus is not increased in patients with moderate to severe atopic dermatitis when pimecrolimus cream 1% is applied under occlusion. [2010]
Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand
dermatitis: a randomized, double-blind trial. [2010]
The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton
syndrome: results from an exploratory study. [2010]
New treatment strategy and assessment questionnaire for external auditory canal
pruritus: topical pimecrolimus therapy and Modified Itch Severity Scale. [2010]
|
